1. Introduction

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths each year, accounting for nearly one-third of all global deaths (World Health Organization [WHO], 2021). This staggering figure underscores the persistent and growing threat of cardiovascular conditions to public health, despite remarkable progress in medical science, technology, and healthcare delivery. The burden of CVD is not uniformly distributed; rather, it varies substantially across geographical regions, socioeconomic groups, and healthcare systems, with low- and middle-income countries (LMICs) disproportionately affected (Prabhakaran et al., 2016). While high-income countries have achieved sustained declines in CVD mortality due to improved treatment and risk factor management, LMICs face rising incidence and mortality rates, driven by urbanization, epidemiological transitions, and limited healthcare infrastructure (Roth et al., 2020).

The spectrum of cardiovascular diseases includes coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic and congenital heart disease, deep vein thrombosis, and pulmonary embolism (WHO, 2021). Collectively, these conditions impose a dual burden of premature mortality and long-term morbidity, thereby straining healthcare systems and hindering social and economic development. For instance, in the United States, the direct and indirect costs of CVD—including healthcare services, medications, and productivity losses—were estimated at $219 billion in 2020 (Tsao et al., 2023). Globally, the economic toll is even more profound; the World Economic Forum projects that non-communicable diseases (NCDs), primarily CVD, will result in cumulative economic losses of $47 trillion between 2010 and 2030 (Bloom et al., 2011). These costs are especially catastrophic in resource-limited countries, where CVD often strikes individuals during their most productive years, pushing families into cycles of poverty and perpetuating inequities.

The global distribution of CVD burden reveals stark regional disparities. Age-standardized CVD mortality rates are highest in Eastern Europe and Central Asia, with countries such as Russia, Bulgaria, and Belarus reporting rates exceeding 500 deaths per 100,000 population (Institute for Health Metrics and Evaluation [IHME], 2022). In contrast, Western Europe, North America, and certain Asia-Pacific countries have seen mortality decline to fewer than 150 deaths per 100,000 population, largely due to public health interventions, improved healthcare access, and widespread use of evidence-based therapies (Ford & Capewell, 2011). However, regions such as South Asia and sub-Saharan Africa are experiencing rapid increases in CVD prevalence, with projections suggesting that India and other South Asian countries will face some of the highest rates of premature CVD mortality globally in the coming decades (Keates et al., 2017).

A key driver of the global CVD epidemic lies in the clustering of modifiable risk factors. Hypertension, diabetes mellitus, dyslipidemia, tobacco use, physical inactivity, obesity, and unhealthy diets collectively account for the majority of CVD cases (Mills et al., 2020; Afshin et al., 2019; Reitsma et al., 2017). For example, hypertension alone affects 1.28 billion adults worldwide, with suboptimal detection and control particularly evident in LMICs (Mills et al., 2020). Diabetes prevalence has quadrupled since 1980, reaching 422 million adults in 2014, with projections estimating 700 million cases by 2045 (WHO, 2016). Meanwhile, tobacco use continues to cause approximately 2 million CVD deaths annually (Reitsma et al., 2017), and physical inactivity contributes significantly to morbidity, with nearly one in four adults failing to meet minimum activity guidelines (Guthold et al., 2018). Dietary risks, particularly excessive sodium intake, inadequate fruit and vegetable consumption, and reliance on processed foods, remain the leading cause of global deaths, linked to 11 million deaths in 2017 alone (Afshin et al., 2019).

Encouragingly, evidence demonstrates that the majority of premature CVD events are preventable. The World Heart Federation (2022) estimates that approximately 80% of premature heart attacks and strokes can be avoided through lifestyle modification and appropriate medical interventions. Primary prevention strategies—ranging from tobacco control to salt reduction initiatives and trans-fat elimination—have proven highly effective in reducing risk factors and improving population health outcomes (Karppanen & Mervaala, 2006; Restrepo & Rieger, 2016; WHO Framework Convention on Tobacco Control, 2019). Secondary prevention measures, including optimal medication adherence and cardiac rehabilitation programs, also yield significant reductions in recurrent events and mortality (Brown & Bussell, 2011; Anderson et al., 2016).

Population-level policy interventions, in particular, stand out for their cost-effectiveness. Tobacco taxation, sugar-sweetened beverage taxes, front-of-package nutrition labeling, and subsidies for healthy foods not only modify individual behavior but also shift environments to facilitate healthier choices (Colchero et al., 2016; Taillie et al., 2020; Afshin et al., 2017). Urban planning policies that promote active transport and walkability further enhance cardiovascular health while yielding co-benefits for environmental sustainability (Sallis et al., 2016). From an economic standpoint, prevention consistently demonstrates strong returns on investment; for every dollar invested in proven NCD interventions, the WHO estimates a return of at least seven dollars in reduced healthcare costs and productivity gains (WHO, 2018).

Despite these advances, significant barriers persist. Healthcare systems in LMICs remain under-resourced and overburdened, limiting access to essential preventive services and medications (WHO, 2020). Workforce shortages, inadequate training, and uneven distribution of healthcare professionals compound these challenges (Ogedegbe et al., 2014). Political and commercial determinants of health also pose obstacles, as powerful industry lobbies resist regulations on tobacco, processed foods, and sugary beverages (Bloom et al., 2011). Moreover, social determinants such as poverty, health literacy, and cultural norms shape individual behaviors and community-level adoption of prevention strategies, further complicating implementation (Jeet et al., 2017).

The urgency of addressing CVD has been further highlighted by the COVID-19 pandemic, which exposed the vulnerability of individuals with pre-existing CVD to severe outcomes and mortality, while simultaneously disrupting healthcare delivery for NCDs (Roth et al., 2020). This experience underscores the need for resilient healthcare systems that integrate infectious and non-communicable disease preparedness. Emerging innovations—including digital health technologies, mobile health interventions, wearable monitoring devices, and precision prevention approaches—hold promise for transforming CVD prevention strategies, particularly in resource-limited settings (Chow et al., 2015; Joseph et al., 2021).

Given the complexity of cardiovascular disease and its multifactorial drivers, effective prevention requires a comprehensive, multi-level strategy. This includes integrating risk factor screening and management into primary care, implementing policy and environmental interventions that promote healthy living, and leveraging community-based and digital innovations to extend reach and sustainability. Moreover, sustained political will, global collaboration, and investment in implementation science are essential to bridge the gap between evidence and practice.

In light of these considerations, this systematic review aims to analyze the current global burden of CVD, synthesize evidence-based prevention strategies, and evaluate public health interventions with demonstrated effectiveness and cost-effectiveness. By consolidating insights from recent studies published between 2015 and 2024, the review seeks to inform future research, policy, and practice, ultimately contributing to global efforts in reducing CVD-related morbidity and mortality.

2. Methodology

This study was designed as a systematic review to synthesize and evaluate evidence regarding the global burden of cardiovascular disease (CVD) and prevention strategies, including individual, community, and policy-level interventions. The methodology adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines to ensure transparency, reproducibility, and scientific rigor. The review protocol was structured to meet the requirements for systematic reviews indexed in PubMed and was informed by methodological guidance outlined in the Cochrane Handbook for Systematic Reviews of Interventions.

Studies were considered eligible if they met specific inclusion criteria. Eligible populations included adults aged 18 years or older from all geographical regions, encompassing high-income, middle-income, and low-income countries. Eligible studies were required to focus on global, regional, or national data on the burden of cardiovascular diseases, including incidence, prevalence, morbidity, mortality, and economic costs, as well as prevention strategies at the primary, secondary, or tertiary level. Only peer-reviewed observational studies (cohort, case-control, cross-sectional), randomized controlled trials (RCTs), quasi-experimental studies, systematic reviews, and meta-analyses were included. To ensure relevance, the review considered articles published between January 2015 and December 2024, and only studies published in English were eligible. Exclusion criteria were applied to case reports, conference abstracts without full text, editorials, opinion pieces, and studies lacking sufficient methodological details.

A comprehensive literature search was carried out across multiple databases, including PubMed/MEDLINE, Scopus, Web of Science, Embase, and the Cochrane Library. In addition, the World Health Organization (WHO) Global Health Observatory was consulted to extract epidemiological statistics. The search strategy was developed in consultation with a medical librarian to maximize both sensitivity and specificity. Controlled vocabulary terms (MeSH) were combined with free-text keywords using Boolean operators. For example, the PubMed search string included: (“Cardiovascular Diseases”[Mesh] OR “heart disease” OR “stroke” OR “CVD” OR “ischemic heart disease” OR “hypertension”) AND (“prevention” OR “risk reduction” OR “lifestyle intervention” OR “public health policy” OR “primary prevention” OR “secondary prevention”) AND (“global burden” OR “epidemiology” OR “mortality” OR “incidence” OR “morbidity” OR “health economics”) AND (“2015/01/01”[Date - Publication] : “2024/12/31”[Date - Publication]). Similar strategies were tailored for other databases, and the reference lists of key studies and systematic reviews were also hand-searched to capture additional relevant publications.

All identified records were imported into EndNote 20 (Clarivate Analytics) for reference management, and duplicates were removed. Screening occurred in two stages. First, two independent reviewers screened titles and abstracts against the inclusion criteria. Second, full-text articles deemed potentially relevant were retrieved and reviewed in detail. Discrepancies at either stage were resolved through discussion, and unresolved disagreements were adjudicated by a third reviewer. The study selection process was documented using the PRISMA 2020 flow diagram.

Data extraction was conducted using a standardized form developed and piloted prior to full use. Extracted data included study identifiers (author, year, journal, country, and region), study design and sample size, population characteristics (age, sex, socioeconomic status, comorbidities), the type of CVD assessed (such as ischemic heart disease, stroke, or hypertension), measures of disease burden (incidence, prevalence, mortality, disability-adjusted life years [DALYs], and years of life lost [YLLs]), prevention strategies examined (lifestyle-based, pharmacological, community-based, or policy-level interventions), and key outcomes (effectiveness, cost-effectiveness, feasibility, barriers, and facilitators). Data were extracted independently by two reviewers, and any differences were reconciled by consensus.

The quality and risk of bias of included studies were assessed using established tools appropriate to study design. Randomized controlled trials were appraised using the Cochrane Risk of Bias Tool (RoB 2), observational studies were assessed with the Newcastle-Ottawa Scale (NOS), and systematic reviews and meta-analyses were evaluated using the AMSTAR 2 checklist. Each study was classified as having low, moderate, or high risk of bias. Quality ratings were used to guide interpretation but not as exclusion criteria.

Given the anticipated heterogeneity of study designs, populations, and outcome measures, a narrative synthesis was primarily employed. Data were synthesized thematically and grouped according to three domains: burden of CVD (including incidence, prevalence, mortality, DALYs, and economic costs by region and income level), prevention strategies (covering primary, secondary, and tertiary interventions across individual, pharmacological, and policy domains), and effectiveness and cost-effectiveness of interventions. Tables and figures were developed to summarize findings across studies. Meta-analysis was not performed due to variability in study design and outcome reporting; however, effect estimates from included studies were presented where available.

As this review synthesized data from previously published studies, ethical approval was not required. Nonetheless, ethical standards in reporting, data handling, and attribution were rigorously maintained. To ensure reproducibility, the full PubMed search strategy, adaptations for other databases, the data extraction template, and risk of bias assessment tools are provided in supplementary materials. All phases of screening, extraction, and synthesis were conducted independently by two reviewers to minimize bias.

3. Global Burden of Cardiovascular Disease

3.1 Epidemiological Overview

Cardiovascular disease (CVD) continues to represent the most significant cause of mortality worldwide and remains a dominant public health challenge. According to the World Health Organization (2021), CVD was responsible for approximately 17.9 million deaths in 2019, accounting for nearly 32% of all global deaths. These deaths are primarily attributable to ischemic heart disease and stroke, which together comprise over 85% of CVD-related mortality. Importantly, the Global Burden of Disease (GBD) Study 2019 revealed a complex epidemiological trend: while the absolute number of deaths from CVD increased by 17.1% between 2010 and 2019, the age-standardized mortality rate declined by 11.8% in the same period, suggesting that population growth and aging are key drivers of the rising number of deaths (Roth et al., 2020).

The global prevalence of CVD varies substantially by region and socioeconomic context. Data from the Institute for Health Metrics and Evaluation (2022) show that Eastern Europe and Central Asia continue to bear the highest age-standardized CVD death rates, with some countries such as Bulgaria, Russia, and Belarus reporting over 500 deaths per 100,000 population. By contrast, high-income countries in Western Europe, North America, and the Asia-Pacific region consistently demonstrate the lowest age-standardized mortality rates, typically under 150 deaths per 100,000 population. These geographic variations underscore the influence of structural health systems, economic development, and the implementation of preventive strategies in shaping CVD outcomes globally.

Despite advances in medical care, the burden of CVD remains closely linked to modifiable risk factors such as hypertension, dyslipidemia, obesity, smoking, physical inactivity, and diabetes. These risk factors are influenced by broader determinants of health, including urbanization, globalization of unhealthy diets, socioeconomic inequalities, and environmental exposures. Therefore, the global epidemiology of CVD reflects both biological risk profiles and the political, economic, and social conditions that affect population health outcomes. Table 1 summarizes the global prevalence, regional variation, and major risk factors contributing to cardiovascular disease worldwide.

3.2 Regional Variations

3.2.1 High-Income Countries

High-income countries (HICs) have witnessed significant progress in reducing CVD mortality over the past four decades. For example, age-adjusted coronary heart disease (CHD) death rates have declined by approximately 70% since the 1980s (Ford & Capewell, 2011). This decline is multifactorial: approximately 40% of the reduction can be attributed to advances in clinical interventions such as revascularization procedures, evidence-based pharmacological treatments, and improvements in acute and chronic CVD care, while around 50% of the improvement is linked to reductions in key population-level risk factors (Ford & Capewell, 2011). Specifically, decreased smoking prevalence, better blood pressure control through widespread antihypertensive treatment, reductions in cholesterol levels due to dietary changes and statin therapy, and improved diabetes management have all contributed to sustained declines in CVD mortality.

Despite these achievements, challenges persist in high-income regions. The growing prevalence of obesity and diabetes, coupled with aging populations, threatens to slow or even reverse some of the gains achieved in prior decades. Furthermore, persistent health inequities mean that marginalized populations within high-income countries—such as ethnic minorities, low-income groups, and individuals with limited access to healthcare—continue to experience disproportionately higher CVD morbidity and mortality rates. Thus, while high-income countries serve as examples of the effectiveness of comprehensive prevention and treatment strategies, ongoing vigilance is necessary to sustain and broaden these improvements.

3.2.2 Low- and Middle-Income Countries

In contrast, low- and middle-income countries (LMICs) bear a disproportionate share of the global CVD burden. Over 80% of global CVD deaths now occur in LMICs, reflecting the rapid epidemiological transition from communicable to non-communicable diseases in these settings (Prabhakaran et al., 2016). This transition is often characterized by rising prevalence of behavioral and metabolic risk factors, such as tobacco use, unhealthy diets high in trans fats and salt, physical inactivity, and uncontrolled hypertension, alongside persistent infectious disease burdens. This dual challenge places enormous strain on fragile health systems, many of which lack the resources to effectively diagnose, treat, and prevent CVD on a large scale.

The situation in Sub-Saharan Africa is particularly concerning. Projections suggest that between 2020 and 2030, the burden of stroke will increase by 27% and that of coronary heart disease by as much as 70% (Keates et al., 2017). Factors such as rapid urbanization, limited access to preventive healthcare, inadequate primary care infrastructure, and insufficient public health policies targeting risk factors contribute to this rise. In South Asia, and particularly India, premature mortality from CVD is significantly higher than global averages. This is partly due to the early onset of metabolic risk factors in the population, including high rates of insulin resistance and diabetes, compounded by environmental stressors, occupational risks, and unequal access to health services.

The rising CVD burden in LMICs underscores the urgent need for context-specific prevention and treatment strategies. Without substantial interventions, the projected increase in CVD cases in these regions could reverse global progress in reducing premature mortality from non-communicable diseases.

3.3 Economic Impact

The impact of CVD extends far beyond the clinical sphere, exerting immense economic and social pressures on households, healthcare systems, and national economies. According to the World Economic Forum, non-communicable diseases—of which CVD constitutes the largest share—are projected to cost the global economy approximately $47 trillion between 2010 and 2030 (Bloom et al., 2011). These costs encompass direct healthcare expenditures, indirect losses due to reduced productivity, and intangible losses related to diminished quality of life.

Direct costs primarily involve the use of healthcare services, including hospitalizations, physician visits, diagnostic tests, medications, surgical procedures, and the use of medical devices such as stents and pacemakers. In many high-income countries, these costs represent a significant proportion of healthcare budgets, and the demand for advanced but costly interventions continues to rise as populations age. In LMICs, where healthcare financing is often inadequate and out-of-pocket payments are common, the direct costs of CVD treatment can be catastrophic for households.

Indirect costs, which include lost productivity due to illness, disability, absenteeism, and premature mortality, may even surpass direct medical costs. When working-age adults are affected by CVD, the economic consequences extend to families, employers, and entire economies. For example, premature death or long-term disability in a primary income earner can reduce household income, increase dependency ratios, and perpetuate cycles of poverty. This effect is especially pronounced in LMICs, where social safety nets and insurance coverage are often weak or absent.

Finally, intangible costs, such as pain, suffering, and reduced quality of life, represent a substantial but less easily quantifiable component of the CVD burden. These costs capture the lived experience of individuals and families coping with chronic illness, disability, or bereavement. While intangible costs are less often measured in economic analyses, they significantly affect overall well-being and underscore the human dimension of the global CVD epidemic.

The economic consequences of CVD highlight the critical importance of investing in prevention. Evidence indicates that cost-effective strategies—such as reducing tobacco use through taxation and legislation, promoting physical activity, improving diets, and ensuring affordable access to essential medicines—can substantially reduce the burden of disease and yield significant economic savings. In this context, prevention not only reduces morbidity and mortality but also serves as a strategic economic investment that benefits individuals, communities, and nations.

4. Major Risk Factors

4.1 Traditional Risk Factors

4.1.1 Hypertension

Hypertension is one of the most well-established and prevalent risk factors for cardiovascular disease, affecting approximately 1.28 billion adults globally (Mills et al., 2020). It represents the leading contributor to CVD mortality and morbidity, with elevated blood pressure responsible for nearly 10.8 million deaths annually, primarily from ischemic heart disease and stroke (Mills et al., 2020). Despite the availability of effective antihypertensive medications and lifestyle interventions, hypertension remains poorly controlled in many parts of the world, particularly in low- and middle-income countries (LMICs), where health systems often face challenges in screening, treatment, and long-term management.

The burden of hypertension is compounded by the fact that it is frequently asymptomatic, leading to delayed diagnosis and under-treatment. The epidemiological transition in LMICs—marked by urbanization, dietary changes, sedentary lifestyles, and increased life expectancy—has contributed to rising hypertension prevalence. Detection rates remain suboptimal, with less than half of hypertensive individuals aware of their condition in many countries, and even fewer achieving adequate blood pressure control. Effective strategies for reducing hypertension-related CVD include population-level interventions such as reducing dietary salt intake, promoting healthier diets, improving access to affordable medications, and strengthening primary healthcare systems to enable early detection and long-term management.

4.1.2 Diabetes Mellitus

Diabetes mellitus is another major traditional risk factor for CVD, with its prevalence growing at alarming rates worldwide. Since 1980, the number of adults living with diabetes has nearly quadrupled, reaching 422 million in 2014 (World Health Organization [WHO], 2016). The International Diabetes Federation (IDF) projects that this number will rise to 700 million by 2045, significantly amplifying the global burden of CVD.

Diabetes increases the risk of cardiovascular disease two- to four-fold, largely due to its effects on vascular biology. Chronic hyperglycemia promotes endothelial dysfunction, accelerates atherosclerosis, and enhances pro-inflammatory and pro-thrombotic pathways. These mechanisms increase susceptibility to ischemic heart disease, stroke, peripheral arterial disease, and heart failure. Importantly, individuals with diabetes often present with clustering of other risk factors, including obesity, hypertension, and dyslipidemia, a constellation commonly referred to as “metabolic syndrome.” This clustering magnifies overall cardiovascular risk.

Despite improvements in glucose-lowering therapies and multidisciplinary care, a significant gap remains between evidence-based treatment guidelines and clinical practice, especially in LMICs where access to affordable medications and monitoring is limited. Public health strategies aimed at diabetes prevention—including promotion of healthy diets, regular physical activity, and obesity reduction—remain critical components of long-term efforts to mitigate CVD burden.

4.1.3 Dyslipidemia

Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), plays a causal role in the development of atherosclerotic cardiovascular disease (ASCVD). LDL-C is directly implicated in the pathogenesis of plaque formation and progression, making it a central target in both primary and secondary prevention of CVD. According to the Global Burden of Disease Study, high cholesterol levels account for approximately 4.4 million deaths each year (GBD 2017 Risk Factor Collaborators, 2018).

High-income countries have achieved notable reductions in population cholesterol levels through a combination of dietary changes, public health campaigns, and widespread statin use. These efforts have contributed substantially to the declines in CVD mortality observed in these regions over recent decades. By contrast, many LMICs are experiencing rising cholesterol levels, driven by nutrition transitions characterized by increased consumption of processed foods, saturated fats, and animal products, combined with reduced intake of fiber-rich fruits and vegetables. This shift places LMICs at heightened risk of accelerating CVD epidemics unless preventive strategies are implemented.

Targeted interventions, including promoting heart-healthy diets, increasing availability of affordable lipid-lowering medications, and strengthening healthcare infrastructure for long-term risk factor management, remain essential in addressing dyslipidemia-related CVD globally.

4.1.4 Tobacco Use

Tobacco use remains one of the most preventable causes of cardiovascular morbidity and mortality worldwide. It is estimated to cause nearly 2 million CVD deaths annually (Reitsma et al., 2017). The cardiovascular hazards of smoking are mediated through several mechanisms, including endothelial dysfunction, increased oxidative stress, heightened platelet activation, pro-thrombotic states, and acceleration of atherosclerotic plaque development. Importantly, exposure to secondhand smoke also increases CVD risk, underscoring the broad public health implications of tobacco use.

One of the most encouraging aspects of tobacco-related CVD risk is its reversibility. Evidence demonstrates that smoking cessation rapidly reduces cardiovascular risk, with significant declines observed within one year of quitting. Over time, risk continues to decline, eventually approaching that of nonsmokers. This underscores the critical importance of comprehensive tobacco control measures, including taxation, restrictions on advertising, public smoking bans, and widespread availability of cessation support programs.

Although tobacco use has declined in many high-income countries due to sustained public health efforts, it remains highly prevalent in many LMICs. Global tobacco control therefore requires coordinated international action alongside region-specific interventions tailored to cultural, economic, and social contexts.

4.2 Lifestyle Risk Factors

4.2.1 Physical Inactivity

Physical inactivity has emerged as a major modifiable risk factor for cardiovascular disease. Globally, nearly 27.5% of adults do not achieve recommended levels of physical activity, a figure that translates to hundreds of millions of individuals at increased risk for adverse cardiovascular outcomes (Guthold et al., 2018). Insufficient physical activity is strongly associated with increased risk of coronary heart disease, stroke, type 2 diabetes, and all-cause cardiovascular mortality.

Conversely, regular physical activity provides profound cardiovascular benefits, including improved endothelial function, enhanced lipid profiles, reduced blood pressure, and increased insulin sensitivity. These benefits are dose-dependent, meaning that even modest increases in activity levels confer measurable reductions in risk. Population-wide interventions promoting active lifestyles—such as safe urban design, promotion of walking and cycling, and workplace wellness programs—can play a crucial role in reducing the global burden of physical inactivity.

4.2.2 Unhealthy Diet

Dietary factors are among the leading contributors to global CVD risk. Poor dietary quality influences CVD risk through multiple pathways, including effects on obesity, blood pressure, serum lipids, and glucose metabolism. The Global Burden of Disease Study identified dietary risks as the leading cause of death worldwide, responsible for 11 million deaths in 2017 (Afshin et al., 2019).

Key dietary patterns associated with elevated CVD risk include high sodium intake, excessive consumption of trans fats and saturated fats, low intake of fruits, vegetables, legumes, and whole grains, and increasing reliance on ultra-processed foods. High sodium intake is particularly problematic, contributing substantially to the global prevalence of hypertension. Similarly, diets high in added sugars and refined carbohydrates promote obesity, insulin resistance, and dyslipidemia, thereby elevating cardiovascular risk.

Promoting healthier dietary practices requires multi-level interventions, including public education, food industry regulation, subsidies for healthier foods, and restrictions on marketing unhealthy products. Successful examples include salt reduction initiatives in the United Kingdom and trans fat bans in several countries, which demonstrate the feasibility and effectiveness of policy-driven dietary interventions.

4.2.3 Obesity

Obesity represents a complex and rapidly growing global health challenge that significantly increases CVD risk. Since 1975, obesity prevalence has tripled, with more than 650 million adults classified as obese in 2016 (WHO, 2020). The pathophysiological mechanisms linking obesity to CVD are multifactorial, involving insulin resistance, chronic inflammation, increased sympathetic nervous system activation, hypertension, and dyslipidemia.

Importantly, not all individuals with obesity carry the same cardiovascular risk. Factors such as fat distribution, metabolic health, genetic predisposition, and comorbid conditions modify the relationship between obesity and CVD outcomes. Central obesity, reflected by waist circumference or waist-to-hip ratio, appears to confer higher cardiovascular risk than overall body mass index (BMI) alone, highlighting the need for more nuanced risk assessment in clinical practice.

The rising prevalence of obesity is strongly tied to societal and environmental changes, including widespread availability of calorie-dense foods, sedentary lifestyles, and urban environments that discourage physical activity. Addressing obesity requires a multifaceted approach, including lifestyle modification, public health interventions, and, in some cases, pharmacological or surgical treatments. Without concerted action, the obesity epidemic is likely to further amplify the global burden of CVD in the coming decades.

5. Evidence-Based Prevention Strategies

Prevention of cardiovascular disease (CVD) remains a cornerstone of global health, given the significant morbidity and mortality associated with the condition. The dual approach of primary and secondary prevention offers a framework for reducing disease burden by targeting both populations at risk and individuals with established CVD. Evidence-based strategies have shown effectiveness at different levels of prevention, ranging from broad public health policies to individualized medical interventions. This section outlines key prevention approaches and highlights the scientific evidence supporting their implementation. Table 2 provides an overview of evidence-based prevention strategies, including population-level and individual-level interventions, their target populations, outcomes, and cost-effectiveness.

5.1 Primary Prevention

Primary prevention aims to avert the onset of CVD in individuals without clinically manifest disease by addressing risk factors and promoting cardiovascular health. Within this category, interventions can be grouped into population-based strategies and high-risk individual approaches.

5.1.1 Population-Based Approaches

Population-based strategies are designed to shift the distribution of risk across entire populations. Following the principle of Geoffrey Rose’s “prevention paradox,” these strategies often yield small benefits for individuals but lead to significant aggregate reductions in CVD incidence and mortality when applied broadly (Rose, 2001).

Tobacco Control Policies

Tobacco remains one of the most preventable causes of CVD. Comprehensive tobacco control programs—including taxation, smoke-free legislation, advertising bans, health warnings, and cessation support—have proven highly effective. For example, the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC), adopted in 2003, provides a global framework for implementing evidence-based tobacco control measures (WHO Framework Convention on Tobacco Control, 2019). Countries implementing strong tobacco control policies have observed reductions in smoking prevalence and corresponding declines in CVD mortality. A case study from the United States demonstrated that clean indoor air laws and tobacco taxation were associated with significant reductions in acute myocardial infarction admissions (Lightwood & Glantz, 2009).

Salt Reduction Initiatives

Excess sodium intake is strongly linked to hypertension, a leading risk factor for CVD. Population-level interventions to reduce salt consumption have demonstrated measurable health benefits. Finland offers a particularly notable example: beginning in the 1970s, nationwide efforts to reduce dietary sodium—including public education campaigns, mandatory labeling, and reformulation of processed foods—led to a 30% decline in average blood pressure and a more than 75% reduction in stroke and ischemic heart disease mortality (Karppanen & Mervaala, 2006). These findings underscore the value of policy-driven nutrition interventions.

Trans Fat Elimination

Industrial trans fatty acids are associated with adverse lipid profiles, systemic inflammation, and increased risk of coronary heart disease. Recognizing these harms, Denmark became the first country to ban industrial trans fats in 2003. Following implementation, the country experienced a significant reduction in CVD mortality, with the greatest benefits observed among socioeconomically disadvantaged groups (Restrepo & Rieger, 2016). Building on this success, the WHO launched the REPLACE initiative, aiming to eliminate industrially produced trans fats from the global food supply by 2023 (World Health Organization, 2019). Countries such as the United States, Canada, and India have since adopted similar policies, reflecting the growing consensus around trans fat elimination as a cost-effective public health intervention.

Collectively, population-based interventions demonstrate that legislative and policy-level strategies can yield substantial long-term benefits, particularly when targeting modifiable environmental determinants of health.

5.1.2 High-Risk Individual Approaches

While population-wide strategies provide broad benefits, targeted interventions for high-risk individuals are essential to achieve optimal prevention outcomes. These approaches involve clinical risk assessment, pharmacological treatment, and intensive lifestyle interventions for those most likely to develop CVD.

CVD Risk Assessment

Systematic risk assessment using validated prediction models enables clinicians to identify individuals at high risk of developing CVD. Tools such as the Framingham Risk Score, the American College of Cardiology/American Heart Association (ACC/AHA) pooled cohort equations, and the WHO/International Society of Hypertension (ISH) risk charts are widely used in different contexts. The WHO/ISH charts, in particular, provide simple, region-specific guidance suitable for low-resource settings (World Health Organization, 2019). Incorporating such tools into routine primary care enables early identification of high-risk individuals and targeted allocation of preventive resources.

Polypill Strategy

The concept of the “polypill”—a fixed-dose combination of medications, typically including aspirin, statins, and antihypertensive agents—has garnered substantial attention as a cost-effective means of improving adherence and reducing CVD risk. Meta-analyses of randomized controlled trials have demonstrated that polypill therapy reduces major cardiovascular events by 20–25% in high-risk populations (Joseph et al., 2021). Furthermore, the simplicity of a single daily pill enhances adherence, particularly in resource-constrained settings where polypharmacy poses challenges. Successful implementation of polypill programs in countries such as Iran and India demonstrates the feasibility and scalability of this strategy.

5.2 Secondary Prevention

Secondary prevention focuses on individuals with established CVD, aiming to prevent recurrence of events such as myocardial infarction, stroke, and heart failure. This category emphasizes optimal medical therapy, lifestyle modification, and comprehensive rehabilitation.

5.2.1 Medication Adherence

Pharmacological therapies, including antiplatelet agents, beta-blockers, ACE inhibitors, and statins, are highly effective for reducing recurrent cardiovascular events. However, poor medication adherence represents a persistent challenge. Studies indicate that only 50–70% of patients adhere to prescribed cardiovascular medications, with adherence declining further over time (Brown & Bussell, 2011). Barriers to adherence include medication cost, complex dosing regimens, side effects, and lack of patient education.

Interventions to improve adherence are multi-dimensional. Simplified dosing regimens (such as once-daily dosing or fixed-dose combinations), mobile health reminder systems, pharmacist-led counseling, and financial assistance programs have all demonstrated effectiveness. Importantly, addressing socioeconomic determinants of adherence—such as affordability and access—is critical to ensure equitable secondary prevention outcomes.

5.2.2 Cardiac Rehabilitation

Cardiac rehabilitation (CR) represents a comprehensive, multidisciplinary intervention designed for patients recovering from CVD events. Programs typically include supervised exercise training, nutritional counseling, smoking cessation support, psychological therapy, and education on medication adherence and lifestyle modification. Evidence from systematic reviews and meta-analyses indicates that CR reduces cardiovascular mortality by 13% and hospital readmissions by 18% (Anderson et al., 2016).

Despite its proven benefits, CR remains underutilized globally. Barriers include limited availability of programs in LMICs, patient reluctance, logistical challenges (e.g., transportation), and inadequate referral practices. Expanding CR access through community-based and home-based models, supported by digital health technologies, represents a promising strategy to overcome these barriers. Such adaptations can improve participation rates and extend the benefits of CR to underserved populations.

6. Public Health Interventions

Cardiovascular disease (CVD) remains the leading cause of death globally, and its prevention requires coordinated action at multiple levels. Public health interventions offer broad-based strategies that complement individual-level prevention approaches, addressing both health system capacity and social determinants of health. Effective interventions range from strengthening primary healthcare services to mobilizing community networks and leveraging digital innovations. This section explores evidence-based public health interventions for CVD prevention, emphasizing integration into health systems, community participation, and digital health solutions.

6.1 Health System Interventions

Health systems form the backbone of effective CVD prevention. Strong, well-coordinated healthcare infrastructure ensures that prevention and treatment strategies reach the population equitably and sustainably. Two major strategies in this context include the integration of CVD prevention into primary healthcare and the use of task shifting and capacity building to address workforce challenges.

6.1.1 Integration of CVD Prevention into Primary Healthcare

Primary healthcare (PHC) serves as the first point of contact for most individuals within the health system, making it an ideal platform for implementing large-scale cardiovascular disease (CVD) prevention. Recognizing this, the World Health Organization (WHO) developed the Package of Essential Noncommunicable Disease (PEN) interventions to guide cost-effective CVD prevention strategies in resource-constrained settings (World Health Organization, 2020). The PEN framework emphasizes simple, evidence-based interventions that can be delivered efficiently by trained primary healthcare workers, ensuring broad population reach while maintaining quality of care.

Key elements of this framework include training healthcare workers to conduct comprehensive CVD risk assessments and provide preventive counseling, which empowers patients to modify risk behaviors. Additionally, ensuring the availability of essential medications—such as antihypertensives, statins, and aspirin—remains a cornerstone of effective primary prevention, as these interventions are both cost-effective and lifesaving. Implementing standardized treatment guidelines further harmonizes care across regions, reducing clinical variability and improving outcomes. The framework also stresses the importance of establishing referral networks to facilitate timely specialist care for individuals identified as very high risk, thereby bridging gaps between primary and tertiary care.

Countries that have successfully integrated CVD prevention into PHC demonstrate measurable improvements in population health. For instance, Brazil’s Family Health Strategy has significantly enhanced hypertension control rates through primary care-led interventions, illustrating the effectiveness of decentralized preventive services (Paim et al., 2011). Such examples underscore that embedding CVD prevention within PHC not only strengthens health systems but also enhances accessibility, equity, and sustainability of interventions, particularly in low- and middle-income countries where specialized care may be limited.

6.1.2 Task Shifting and Capacity Building

Workforce shortages remain a critical challenge for CVD prevention, especially in low- and middle-income countries (LMICs). Task shifting—redistributing tasks from physicians to nurses, pharmacists, or community health workers (CHWs)—has emerged as a pragmatic solution. Evidence indicates that trained non-physician providers can manage hypertension and diabetes effectively while maintaining high quality of care (Ogedegbe et al., 2014).

For instance, the WHO’s HEARTS technical package encourages task shifting as part of integrated CVD management. Pharmacist-led interventions in high-income countries have also been associated with significant improvements in medication adherence and blood pressure control (Santschi et al., 2014). Importantly, capacity building through ongoing training, supportive supervision, and provision of decision-support tools ensures sustainability of these workforce innovations.

6.2 Community-Based Interventions

Community-based programs extend prevention beyond health facilities by addressing behavioral risk factors and engaging populations directly. By leveraging trust and local knowledge, these initiatives can improve health literacy, enhance access to care, and create supportive environments for healthy lifestyles.

6.2.1 Community Health Worker Programs

Community health workers (CHWs) serve as vital links between health systems and communities, especially in underserved areas. They can provide tailored health education, encourage lifestyle modification, promote medication adherence, and facilitate referrals. Systematic reviews have confirmed that CHW-led interventions improve blood pressure control, enhance adherence to medications, and foster healthier behaviors (Jeet et al., 2017).

In India, the mPower Heart project trained CHWs to use decision-support software for hypertension and diabetes management. Results showed significant improvements in blood pressure and glucose control (Patel et al., 2016). These findings underscore how CHWs, when adequately trained and supported, can deliver impactful CVD prevention at scale.

6.2.2 Workplace Health Programs

Workplace interventions represent another effective platform for CVD prevention, as they reach adults during their most productive years. Comprehensive workplace programs that combine health screenings, education, and environmental modifications (such as healthier cafeteria options and opportunities for physical activity) have been shown to reduce risk factors and lower healthcare costs.

For example, Johnson & Johnson’s long-term workplace wellness program demonstrated sustained reductions in smoking rates, blood pressure, and obesity, along with a strong return on investment (Goetzel et al., 2014). Importantly, workplace programs can also address psychosocial stress, a recognized contributor to CVD, by incorporating mental health support.

6.3 Digital Health Interventions

The rapid expansion of mobile technology and digital platforms has created new opportunities for scalable, cost-effective CVD prevention. Digital interventions can overcome barriers of distance, cost, and workforce shortages, making them particularly relevant for LMICs.

6.3.1 Mobile Health (mHealth) Technologies

Mobile health (mHealth) interventions use mobile phones and text messaging to support behavior change, improve adherence, and facilitate communication between patients and providers. The effectiveness of mHealth is well documented. For instance, the TEXT ME trial in Australia demonstrated that text messages delivering motivational and educational content reduced LDL cholesterol, blood pressure, and body mass index, and led to an 8% reduction in major cardiovascular events among high-risk patients (Chow et al., 2015).

Meta-analyses further support mHealth for smoking cessation, weight loss, and improved adherence to medications (Armanasco et al., 2017). In LMICs, where mobile phone penetration is high, mHealth holds promise as a low-cost solution to bridge gaps in healthcare access.

6.3.2 Telemedicine and Remote Monitoring

Telemedicine expands access to specialist care for populations in remote or underserved areas. It allows for virtual consultations, ongoing monitoring, and rapid adjustments in treatment plans. Remote monitoring technologies—such as home blood pressure devices, wearables, and smartphone applications—facilitate early detection of complications and enable personalized feedback.

Evidence indicates that telemedicine can significantly improve hypertension control and secondary prevention outcomes (Omboni et al., 2020). During the COVID-19 pandemic, telehealth adoption accelerated worldwide, further demonstrating its utility for CVD management when in-person care is limited. Hybrid care models that combine in-person visits with remote monitoring may represent the future of chronic disease management.

Public health interventions for CVD prevention must combine health system strengthening, community engagement, and digital innovation. Integrating CVD prevention into primary healthcare ensures equitable, population-wide access to essential services, while task shifting addresses workforce shortages and builds system resilience. Community-based approaches, such as CHW programs and workplace health initiatives, extend prevention beyond clinical settings, embedding it within daily life. Finally, digital health solutions—including mHealth and telemedicine—offer scalable, cost-effective innovations to address persistent gaps in access and continuity of care.

Ultimately, sustainable progress against CVD will require a multi-sectoral approach, aligning health policies with social, economic, and technological strategies. Strengthening collaborations between governments, health systems, communities, and private industry will be critical to achieving the global target of reducing premature CVD mortality by one-third by 2030, as outlined in the United Nations Sustainable Development Goals.

7. Policy Interventions and Regulatory Approaches

Public policy interventions and regulatory frameworks are central to cardiovascular disease (CVD) prevention because they address the structural and environmental determinants of health that shape individual behavior. Unlike clinical and community-based interventions that often target high-risk individuals, policy measures have broad population-level effects and can achieve long-term reductions in CVD risk. Evidence demonstrates that fiscal policies such as taxation and subsidies, as well as regulatory approaches including food labeling, marketing restrictions, and built environment policies, can significantly influence dietary habits, physical activity, and consumption of harmful products. This section examines these interventions in detail, highlighting their effectiveness, challenges, and role in achieving sustainable population health outcomes.

7.1 Fiscal Policies

Fiscal policies use economic incentives and disincentives to shape consumer choices, particularly regarding diet and lifestyle behaviors. They are among the most cost-effective and scalable interventions for reducing CVD risk factors.

7.1.1 Taxation of Unhealthy Products

Taxation of tobacco, alcohol, and sugar-sweetened beverages (SSBs) is a proven strategy to curb consumption of products directly linked to CVD risk. The World Health Organization (2015) recommends tobacco excise taxes of at least 70% of retail prices to maximize public health benefits. Countries adopting such measures have consistently demonstrated reductions in tobacco use and related morbidity. For example, in the Philippines, the “sin tax” reform of 2012 significantly increased tobacco prices, leading to reduced prevalence of smoking and increased government revenues for health programs (Kaiser et al., 2016).

SSB taxation has also emerged as an important policy tool against obesity, diabetes, and CVD. Mexico’s SSB tax, implemented in 2014, led to a 5.2% decline in purchases in the first year and greater reductions among low-income households (Colchero et al., 2016). Similar outcomes have been observed in Berkeley, California, where an SSB excise tax resulted in a 21% drop in SSB consumption after one year (Falbe et al., 2016). Beyond reducing consumption, such taxes encourage reformulation by manufacturers to reduce sugar content in beverages, amplifying health gains at the population level.

Alcohol taxation also contributes to lowering CVD risk by reducing excessive consumption. Studies from Nordic countries show that higher alcohol taxes are associated with reductions in cardiovascular mortality and hospitalizations (Anderson et al., 2021). Importantly, fiscal policies not only improve health outcomes but also generate revenue that governments can reinvest into health promotion and universal health coverage.

7.1.2 Subsidies for Healthy Foods

While taxation reduces demand for unhealthy products, subsidies increase affordability of healthier options. Economic modeling studies indicate that subsidies of 10–30% on fruits and vegetables could prevent tens of thousands of CVD deaths annually while remaining highly cost-effective (Afshin et al., 2017). Subsidies can particularly benefit low-income households, who are disproportionately burdened by diet-related chronic diseases.

The U.S. Supplemental Nutrition Assistance Program (SNAP) pilot that provided a 30% subsidy for fruits and vegetables demonstrated increases in both consumption and nutrient intake, with projected long-term reductions in healthcare costs (Bartlett et al., 2014). Similarly, a randomized controlled trial in South Africa found that discounts on healthy foods significantly increased purchases of fruits, vegetables, and whole grains while reducing purchases of sugary beverages (An et al., 2013).

Combining taxation of unhealthy foods with subsidies for healthy foods can produce synergistic effects. For instance, modeling in the United Kingdom suggested that pairing an SSB tax with subsidies for fruits and vegetables could avert more CVD deaths and reduce health inequalities more effectively than either policy alone (Mytton et al., 2012).

7.2 Regulatory Interventions

Regulatory strategies directly influence the food environment and physical activity opportunities by shaping what products are available, how they are marketed, and how urban spaces are designed. These approaches are often highly sustainable because they alter the structural determinants of health.

7.2.1 Food Labeling and Marketing Restrictions

Clear and accessible food labeling helps consumers make informed decisions while incentivizing industry reformulation. Traditional back-of-package labels often fail to influence consumer choices, whereas front-of-package (FOP) warning labels have demonstrated greater impact. In Chile, a 2016 law mandating warning labels on foods high in sugar, sodium, saturated fat, and calories, coupled with marketing restrictions, resulted in significant reductions in household purchases of sugary drinks and unhealthy foods (Taillie et al., 2020).

Similar approaches in Peru and Mexico have shown reductions in purchases of labeled products, suggesting the transferability of such interventions across diverse contexts (Corvalán et al., 2019). The traffic light system in Ecuador, where foods are labeled red, yellow, or green based on nutritional content, has also shown promise in guiding healthier consumer behavior (Freire et al., 2017).

Marketing restrictions targeting children are another critical regulatory approach. Children are particularly vulnerable to food advertising, which often promotes high-calorie, nutrient-poor foods. Evidence suggests that restricting such marketing reduces children’s exposure to unhealthy food advertising and influences dietary preferences (Boyland et al., 2016).

7.2.2 Built Environment Policies

The built environment—comprising urban design, transportation systems, and access to recreational spaces—strongly influences physical activity and thus CVD risk. Policies promoting walkable neighborhoods, safe cycling infrastructure, and green spaces are associated with increased levels of daily physical activity (Sallis et al., 2016). For example, residents of neighborhoods with higher walkability scores engage in more active transportation and have lower obesity rates (Frank et al., 2006).

“Complete Streets” policies, which design roads to accommodate pedestrians, cyclists, and public transit users, encourage active transportation while reducing reliance on private vehicles. Evidence from the United States demonstrates that such policies increase walking and cycling while improving safety for non-motorized road users (McCann & Rynne, 2010). Similarly, public transportation policies that increase accessibility and affordability of transit options indirectly promote physical activity by encouraging walking to and from transit stops.

Green urban planning also plays a protective role. Access to parks and recreational facilities is associated with reduced CVD mortality and improved mental health (Nieuwenhuijsen et al., 2017). These environmental modifications not only improve cardiovascular health but also yield co-benefits such as reduced air pollution and enhanced climate resilience.

Policy and regulatory interventions represent some of the most powerful tools in the prevention of cardiovascular disease, as they modify the upstream determinants of health behaviors. Fiscal measures such as taxation of unhealthy products and subsidies for fruits and vegetables influence affordability and consumption patterns, while regulatory strategies like food labeling, marketing restrictions, and built environment improvements reshape the environments in which choices are made.

The evidence is clear: well-designed fiscal and regulatory policies are cost-effective, equitable, and sustainable, with potential to reduce health disparities and generate broader social benefits. However, implementation often faces resistance from powerful commercial interests, requiring political will, public support, and intersectoral collaboration.

Ultimately, the successful prevention of CVD will depend on integrating policy measures with healthcare and community-based strategies, ensuring that individuals are supported in making healthier choices within environments that enable them. Aligning these interventions with the Sustainable Development Goals and WHO’s Global Action Plan for the Prevention and Control of NCDs will be critical to reducing premature CVD mortality worldwide.

8. Cost-Effectiveness Analysis

Cost-effectiveness analysis (CEA) is a cornerstone of health economics and policy decision-making in cardiovascular disease (CVD) prevention. Given the global economic burden of CVD—estimated at $1 trillion annually in direct and indirect costs—resource allocation to maximize population health outcomes is crucial (Bloom et al., 2012). Policymakers, health systems, and international organizations increasingly rely on economic evaluations to prioritize interventions that not only improve health but also deliver value for money. This section critically examines the methods, evidence, and strategic implications of cost-effectiveness analysis in CVD prevention.

8.1 Economic Evaluation Methods

Economic evaluation of CVD prevention interventions typically employs cost-effectiveness analysis (CEA) or its extensions, such as cost-utility analysis (CUA). These methods measure the incremental costs of interventions relative to their health outcomes, often expressed as cost per quality-adjusted life year (QALY) or disability-adjusted life year (DALY) averted (Drummond et al., 2015). QALYs incorporate both life expectancy and health-related quality of life, while DALYs emphasize years of healthy life lost due to premature mortality or disability.

The World Health Organization (WHO) Commission on Macroeconomics and Health established that interventions costing less than three times per capita GDP per QALY gained are cost-effective, and those costing less than the per capita GDP are considered highly cost-effective (WHO, 2001). Although this benchmark has guided global health policy, it has also faced criticism for being overly simplistic and not accounting for opportunity costs or local budget constraints (Ochalek et al., 2018).

CEA models in CVD prevention typically use decision-analytic frameworks such as Markov models or microsimulation models that project costs and outcomes over time. These models incorporate risk factor trajectories, intervention effectiveness, healthcare utilization, and mortality to estimate long-term health and economic impacts (Gaziano et al., 2017). The robustness of these evaluations depends on data quality, assumptions regarding adherence, and generalizability across settings.

8.2 Cost-Effectiveness of Prevention Strategies

The cost-effectiveness of CVD prevention varies considerably depending on whether interventions are population-based (structural and policy approaches) or individual-based (clinical and behavioral programs).

8.2.1 Population-Based Interventions

Population-level interventions generally demonstrate excellent cost-effectiveness because they target entire populations, often at relatively low implementation costs. Salt reduction policies, for example, address high sodium intake, a major contributor to hypertension and cardiovascular disease (CVD). Modeling studies indicate that implementing policy measures—such as food reformulation, labeling, and mass media campaigns—to reduce population sodium intake costs approximately $500–$2,000 per quality-adjusted life year (QALY) gained, ranking among the most cost-effective strategies globally (Cobiac et al., 2012). The United Kingdom’s salt reduction program, which combined voluntary industry reformulation and public awareness campaigns, contributed to a 15% decline in population sodium intake and was associated with reductions in stroke and ischemic heart disease mortality (He et al., 2014).

Similarly, trans fat elimination policies, which aim to remove industrial trans fatty acids (iTFAs) from the food supply, are highly cost-effective, with estimated costs of $1,000–$3,000 per QALY gained. Denmark’s early trans fat ban in 2003 resulted in substantial reductions in cardiovascular mortality without increasing food costs (Restrepo & Rieger, 2016). Building on this success, the World Health Organization launched the REPLACE initiative, targeting global elimination of iTFAs by 2023—a measure expected to save millions of lives at minimal cost.

Tobacco taxation is another highly cost-effective population-level intervention, costing approximately $100–$500 per QALY gained, as it reduces consumption while generating fiscal revenue (Verguet et al., 2015). Countries such as the Philippines and Turkey have demonstrated that aggressive tobacco excise tax reforms can lower smoking prevalence and simultaneously support the expansion of universal health coverage (Kaiser et al., 2016).

Although newer and less widespread, sugar-sweetened beverage (SSB) taxation has also shown promise, with cost estimates ranging from $2,000–$5,000 per QALY gained. In Mexico, the 2014 SSB tax led to a sustained 7.6% reduction in purchases by the second year, contributing to lower rates of obesity, diabetes, and subsequent CVD incidence (Colchero et al., 2017).

Overall, population-based approaches stand out for their scalability, sustainability, and equity. They particularly benefit lower-income groups, who are more responsive to price-based interventions, thereby reducing health disparities and disproportionately lowering disease burden across vulnerable populations.

8.2.2 Individual-Based Interventions

Individual-level interventions, while highly effective for high-risk populations, often demonstrate greater variability in cost-effectiveness due to higher implementation costs and challenges with adherence. Statin therapy for high-risk individuals, for example, reduces major cardiovascular events by approximately 25%, and its cost-effectiveness has improved with the availability of generic formulations. Economic evaluations estimate costs of $3,000–$10,000 per quality-adjusted life year (QALY) gained for secondary prevention and high-risk primary prevention, though benefits are less pronounced in lower-risk populations (Cholesterol Treatment Trialists’ Collaboration, 2019).

Antihypertensive therapies for managing elevated blood pressure are also cost-effective, with estimates ranging from $2,000–$8,000 per QALY gained, particularly among middle-aged adults with higher baseline cardiovascular risk. However, ensuring long-term adherence remains a challenge, as rates often fall below 50% after one year (Burnier & Egan, 2019). Integrating treatment with community health workers or employing digital adherence tools may improve sustained engagement and overall cost-effectiveness.

Diabetes management programs, including lifestyle interventions and intensive clinical management for individuals with type 2 diabetes, demonstrate cost-effectiveness ratios of $5,000–$15,000 per QALY gained. The U.S.-based Diabetes Prevention Program (DPP) showed that intensive lifestyle modification not only delayed diabetes onset but also delivered favorable cost-utility outcomes over extended follow-up periods (Herman et al., 2012).

Cardiac rehabilitation following acute coronary syndromes provides $4,000–$12,000 per QALY gained by reducing recurrent cardiovascular events and improving quality of life (Anderson et al., 2016). Despite these benefits, participation rates remain low worldwide, often below 20%, limiting the population-level impact. Expanding home-based and digital rehabilitation models may enhance accessibility and scalability.

In contrast to population-based policies, individual-level interventions are resource-intensive and may exacerbate health inequalities if access is limited to wealthier or urban populations. Therefore, their effectiveness is maximized when integrated into universal health coverage frameworks and supported by robust healthcare system infrastructure.

8.3 Return on Investment

CVD prevention is not only cost-effective but also yields substantial economic returns through reduced healthcare costs, increased productivity, and enhanced economic growth.

The WHO (2018) estimates that every $1 invested in proven interventions for major NCDs returns at least $7. For CVD specifically, modeling studies project return-on-investment (ROI) ratios of 5:1 to 8:1 for comprehensive prevention programs (Bloom et al., 2011). For example, implementing a global package of cost-effective CVD interventions—including tobacco control, salt reduction, and scaling up essential medicines—could avert 18 million deaths by 2030 while yielding economic benefits exceeding $350 billion (Bertram et al., 2018).

At the national level, the U.S. Million Hearts Initiative aimed at preventing one million heart attacks and strokes over five years demonstrated how coordinated prevention efforts can reduce healthcare costs and improve productivity. Similarly, China’s national salt reduction program, projected to save $1.4 trillion in healthcare costs by 2030, illustrates the massive macroeconomic benefits of preventive policy (Webster et al., 2017).

Strategically, ROI arguments are persuasive for policymakers and finance ministries because they link health to economic growth and fiscal sustainability. By framing CVD prevention as an investment rather than an expenditure, advocates can strengthen political commitment and secure long-term funding.

Cost-effectiveness analysis highlights the tremendous value of investing in CVD prevention. Population-based strategies—such as salt reduction, trans fat elimination, tobacco taxation, and SSB taxes—are consistently among the most cost-effective interventions, combining low implementation costs with broad impact. Individual-based interventions—such as statin therapy, hypertension treatment, diabetes management, and cardiac rehabilitation—offer substantial benefits in high-risk groups but require strategic targeting and sustained adherence.

Beyond cost-effectiveness ratios, the return on investment framework demonstrates that prevention generates large economic dividends, strengthening health systems, productivity, and economic growth. The evidence is clear: comprehensive prevention packages that integrate both population-wide and individual-based interventions represent some of the most powerful tools available to combat CVD and achieve the Sustainable Development Goals (SDGs).

Future research should refine economic models to incorporate distributional equity, long-term adherence, and health system integration, ensuring that cost-effectiveness analysis continues to guide strategic, equitable, and sustainable CVD prevention policies worldwide.

9. Implementation Challenges and Barriers

Effective implementation of cardiovascular disease (CVD) prevention strategies faces multifaceted challenges at the health system, political, and individual levels. Despite robust evidence supporting population-based and individual-level interventions, translating these into sustainable programs remains a persistent barrier worldwide. Understanding these implementation challenges is critical to developing context-specific solutions that maximize health outcomes and equity.

9.1 Healthcare System Barriers

9.1.1 Resource Constraints

One of the most substantial barriers to CVD prevention is the limited availability of financial resources, particularly in low- and middle-income countries (LMICs). Health budgets in these settings are often dominated by urgent priorities such as infectious disease control, maternal and child health, and emergency care, leaving non-communicable disease (NCD) prevention underfunded (Bloom et al., 2011). Resource scarcity impacts the availability of essential medications, diagnostic equipment, and preventive services such as blood pressure and cholesterol screening.

Furthermore, CVD prevention often requires long-term investment in health promotion, public education, and policy implementation. Interventions such as nationwide salt reduction programs, tobacco control policies, or cardiovascular screening programs necessitate upfront expenditure, which can be politically challenging in resource-constrained settings (Gaziano et al., 2017). In many LMICs, even highly cost-effective interventions face delays in implementation due to insufficient funding mechanisms and fragmented health financing systems.

9.1.2 Workforce Capacity

Healthcare workforce limitations constitute another critical barrier. Many countries, especially in rural and underserved regions, suffer from shortages of trained healthcare professionals, including physicians, nurses, and allied health workers. Even where personnel are available, inadequate training in CVD prevention and management reduces the quality and effectiveness of interventions (Ogedegbe et al., 2014).

Task-shifting strategies—delegating preventive care responsibilities to community health workers, nurses, or pharmacists—have shown promise in addressing workforce shortages. Studies indicate that properly trained non-physician providers can effectively screen for hypertension, diabetes, and dyslipidemia while delivering lifestyle counseling (Jeet et al., 2017). However, scaling such approaches requires investment in standardized training curricula, supervision systems, and sustainable remuneration models, which are often underdeveloped in LMIC contexts.

Additionally, high workloads and competing clinical responsibilities can limit healthcare workers’ capacity to deliver preventive interventions. For example, primary care providers in many countries prioritize acute care visits over preventive counseling, reducing the reach of CVD prevention programs (WHO, 2020).

9.2 Political and Policy Barriers

9.2.1 Industry Opposition

A key obstacle to population-based CVD prevention is resistance from commercial interests whose products contribute to cardiovascular risk. Tobacco, food, and beverage industries often oppose taxation, labeling, and marketing restrictions that could reduce consumption of their products. Industry tactics include lobbying against regulation, funding research to challenge the evidence base, and promoting voluntary self-regulation as a substitute for legally mandated policies (Colchero et al., 2016; Taillie et al., 2020).

This opposition can significantly delay policy implementation, particularly in countries where regulatory frameworks are weak or political influence is highly concentrated. For example, attempts to regulate sugar-sweetened beverages have faced sustained opposition in multiple LMICs despite compelling evidence of their role in obesity and diabetes, both major CVD risk factors. Strategic engagement with civil society, transparency in policymaking, and leveraging global frameworks such as the WHO Framework Convention on Tobacco Control are essential to counter industry resistance (WHO, 2015).

9.2.2 Political Will and Leadership

Sustained political commitment is critical for the success of CVD prevention strategies, which require long-term investment and consistent implementation. Changes in government priorities, election cycles, or leadership can disrupt ongoing programs, reducing their effectiveness and eroding public trust. Policies such as national salt reduction campaigns or trans fat bans often span decades, demanding continuity that short-term political agendas may not provide (Karppanen & Mervaala, 2006).

In addition, competing priorities, including economic development and infrastructure projects, can limit policymakers’ willingness to adopt regulations perceived as economically restrictive. Countries with successful long-term prevention strategies, such as Finland’s salt reduction program, highlight the importance of bipartisan support, multi-sectoral collaboration, and integration into broader health and social development plans (He et al., 2014).

9.3 Individual and Community Barriers

9.3.1 Health Literacy

At the individual level, low health literacy significantly impedes adoption of preventive behaviors. Individuals may lack understanding of cardiovascular risk factors, the benefits of lifestyle modification, or the importance of medication adherence. Misconceptions and cultural beliefs can further reduce the uptake of interventions, for example, reluctance to reduce salt intake due to taste preferences or the perception that hypertension is asymptomatic and therefore harmless (Guthold et al., 2018).

Health literacy barriers are particularly pronounced in marginalized populations, including rural communities, low-income groups, and older adults. Evidence demonstrates that educational interventions, culturally tailored counseling, and digital health tools can improve knowledge, motivation, and self-management, but these approaches require sustained investment and local adaptation (Chow et al., 2015).

9.3.2 Socioeconomic Factors

Socioeconomic constraints further limit effective implementation of CVD prevention strategies. Poverty, food insecurity, limited access to healthcare services, and competing daily survival needs can prevent individuals from adopting healthy behaviors or accessing preventive care. For example, low-income households may rely on high-sodium processed foods due to affordability, despite awareness of dietary risks (Afshin et al., 2019). Similarly, costs associated with medications, transportation to clinics, or participation in structured exercise programs can restrict engagement in preventive interventions.

These socioeconomic barriers contribute to health inequities, as the individuals at highest risk for CVD are often least able to benefit from available prevention programs. Addressing these inequities requires multi-sectoral approaches, including subsidies for healthy foods, community-based interventions, workplace wellness programs, and social protection policies that reduce financial barriers to care (Goetzel et al., 2014; Jeet et al., 2017).

9.4 Strategic Considerations for Overcoming Barriers

Addressing implementation challenges in cardiovascular disease (CVD) prevention requires systematic, multi-level strategies that operate across health systems, policy frameworks, communities, and equity-focused programs. Strengthening health systems is fundamental, involving the integration of CVD prevention into primary healthcare, enhancement of workforce training, and the strategic use of task-shifting to expand service coverage efficiently. The World Health Organization’s Package of Essential Noncommunicable Disease (PEN) interventions offers a practical framework for resource-limited settings to implement scalable and cost-effective preventive measures (World Health Organization, 2020). Policy and regulatory alignment is equally critical, as sustained political commitment, effective enforcement of regulations, and strategies to counter industry opposition are necessary to maintain long-term prevention programs. Engaging civil society, aligning national policies with international frameworks, and clearly demonstrating the economic benefits of preventive interventions can reinforce political will and facilitate policy adoption (Verguet et al., 2015).

Community engagement and health education are vital for increasing uptake and sustainability of prevention programs. Tailoring educational initiatives to local cultural contexts, improving general health literacy, and empowering communities to participate actively in health promotion activities can significantly enhance the effectiveness of interventions (Chow et al., 2015). Equity-focused strategies further strengthen these efforts by ensuring that high-risk and underserved populations receive targeted interventions. Examples include providing subsidies for healthy foods, deploying mobile health technologies, and designing programs specifically to reach socioeconomically disadvantaged groups, thereby reducing health disparities and improving overall cost-effectiveness (Afshin et al., 2017).

Finally, robust monitoring and evaluation mechanisms are essential for sustaining the impact of CVD prevention initiatives. Continuous surveillance, regular outcome evaluation, and adaptive program design allow interventions to remain effective, responsive, and scalable over time, enabling policymakers and implementers to make evidence-based adjustments in response to changing population needs and emerging health challenges. Collectively, these integrated strategies provide a comprehensive approach to overcoming implementation barriers, ensuring that evidence-based CVD prevention measures achieve meaningful and equitable health outcomes across diverse populations.

Implementation of CVD prevention strategies is constrained by resource limitations, workforce shortages, political challenges, industry opposition, low health literacy, and socioeconomic inequities. These barriers are particularly pronounced in LMICs but are also relevant in high-income settings where policy inertia, cultural beliefs, and access disparities persist. Addressing these challenges requires integrated, multi-sectoral approaches that combine health system strengthening, policy advocacy, community engagement, and equity-focused strategies. Successful implementation is not merely a technical exercise but a strategic endeavor linking evidence-based interventions to sustainable political commitment, economic rationale, and social acceptability. Only through coordinated efforts at all levels can the global burden of CVD be meaningfully reduced.

10. Future Directions and Innovations

The landscape of cardiovascular disease (CVD) prevention is rapidly evolving, driven by advances in precision medicine, digital health technologies, and a growing recognition of the intersection between non-communicable diseases (NCDs) and global health security. These innovations promise to enhance the effectiveness, efficiency, and equity of CVD prevention strategies, although significant challenges remain in their implementation and scalability.

10.1 Precision Prevention

Precision prevention represents a transformative approach to CVD risk reduction by tailoring interventions to the individual’s genetic, biochemical, and lifestyle profiles. Advances in genomics have enabled the development of polygenic risk scores, which aggregate the effects of multiple genetic variants to predict an individual’s predisposition to cardiovascular events. Evidence suggests that individuals with high polygenic risk derive the greatest benefit from early intervention, including aggressive lifestyle modification, pharmacotherapy, and risk factor management (Khera et al., 2018). In addition to genomics, biomarker discovery has facilitated more nuanced risk stratification, incorporating indicators such as high-sensitivity C-reactive protein, lipoprotein(a), and troponins to identify subclinical disease and tailor preventive strategies accordingly (Ridker et al., 2019).

Artificial intelligence (AI) and machine learning are increasingly integrated into precision prevention, enabling the analysis of complex datasets to predict disease trajectories and optimize intervention timing. AI algorithms can combine genetic, clinical, behavioral, and environmental data to identify individuals at highest risk and recommend personalized intervention pathways. Despite these advancements, challenges persist. Cost and accessibility of genomic testing and biomarker assays remain prohibitive in low- and middle-income countries (LMICs), raising concerns about widening health disparities. Ethical considerations, including data privacy, informed consent, and equitable access, are critical for ensuring that precision prevention benefits are broadly distributed. Furthermore, robust evidence from randomized trials and real-world implementation studies is still needed to validate the clinical and cost-effectiveness of these personalized approaches (Ingelsson & Lind, 2020).

10.2 Digital Health Innovation

Digital health technologies offer scalable, data-driven solutions to enhance CVD prevention across populations. Wearable devices, such as smartwatches and fitness trackers, allow continuous monitoring of heart rate, blood pressure, physical activity, sleep patterns, and other physiological parameters. These devices facilitate early detection of abnormal cardiovascular trends and support real-time feedback for behavioral modification. Integration with mobile applications can enable personalized health coaching, medication reminders, and goal-setting, improving adherence to lifestyle and pharmacologic interventions (Steinhubl et al., 2015).

AI and machine learning algorithms are central to analyzing the vast amounts of data generated by digital health technologies. Predictive analytics can identify subtle patterns indicative of impending cardiovascular events, allowing timely preventive interventions. Moreover, these technologies can optimize population-level strategies by identifying high-risk clusters and evaluating intervention effectiveness. Remote patient monitoring and telemedicine platforms further expand access to preventive care, particularly in rural or underserved regions, by bridging gaps in specialist availability and overcoming geographical barriers (Kitsiou et al., 2017).

Despite the promise of digital health, several limitations must be addressed. Device accuracy, interoperability across platforms, user engagement, and data privacy are ongoing concerns. Moreover, the digital divide may limit equitable access, with vulnerable populations potentially excluded from these innovations. Regulatory frameworks, standards for validation, and reimbursement policies are essential to ensure safe, effective, and sustainable integration of digital technologies into routine CVD prevention (Kitsiou et al., 2017; Steinhubl et al., 2015).

10.3 Global Health Security and Non-Communicable Diseases

The COVID-19 pandemic has underscored the complex interplay between infectious diseases and NCDs, particularly CVD. Individuals with pre-existing cardiovascular conditions experienced higher rates of severe illness, hospitalization, and mortality from COVID-19 (Clerkin et al., 2020). Concurrently, pandemic-related disruptions to healthcare delivery, including postponed screenings, reduced outpatient visits, and interruptions in chronic disease management, exacerbated CVD risk and highlighted vulnerabilities in global health systems. These experiences emphasize the need to integrate NCDs, including CVD, into global health security and pandemic preparedness frameworks.

Future health security strategies must prioritize continuity of care for individuals with chronic conditions during public health emergencies. Strengthening health system resilience involves ensuring access to essential medications, leveraging telemedicine and remote monitoring, and maintaining preventive services during crises. Furthermore, global collaboration is critical to establish data-sharing platforms, harmonize surveillance systems, and develop guidelines for CVD management during infectious disease outbreaks. Investment in health system capacity, workforce training, and digital infrastructure can simultaneously improve pandemic preparedness and advance long-term CVD prevention goals (WHO, 2021).

10.4 Integrative and Multi-Level Approaches

The future of CVD prevention lies in integrative approaches that combine precision medicine, digital health, and population-level interventions. Multi-level strategies that address individual, community, and systemic determinants of cardiovascular health can amplify impact and sustainability. For example, integrating AI-driven risk stratification with community health worker programs can ensure that high-risk individuals in underserved populations receive tailored interventions. Policy initiatives, such as fiscal incentives for healthy behaviors and urban design promoting active living, can synergize with technological and clinical innovations to reduce overall CVD burden.

Strategic investment in research and implementation science is critical to ensure that innovations translate into measurable population health benefits. This includes rigorous evaluation of cost-effectiveness, scalability, and equity of emerging interventions. Collaborative partnerships among governments, academia, industry, and civil society can facilitate dissemination, foster innovation, and ensure that advances benefit diverse populations globally.

10.5 Challenges and Ethical Considerations

While these future directions hold promise, significant challenges remain. High costs, limited infrastructure, data privacy concerns, and potential inequities in access may limit widespread adoption, particularly in LMICs. Ethical considerations around the use of personal health data, algorithmic bias, and informed consent are paramount, especially when leveraging AI and genomics in prevention programs. Policymakers and healthcare leaders must balance technological innovation with equitable access, affordability, and social responsibility.

In conclusion, the future of CVD prevention is poised to be shaped by precision medicine, digital health innovations, and integrated global health strategies. These approaches offer opportunities to enhance risk prediction, personalize interventions, and strengthen health system resilience. However, their success depends on addressing challenges related to cost, accessibility, equity, and ethics, while fostering collaboration across sectors. By combining technological advancements with evidence-based public health strategies, the global community can move toward more effective, sustainable, and equitable CVD prevention worldwide.

11. Discussion and Conclusions

Cardiovascular disease (CVD) remains the leading cause of global morbidity and mortality, accounting for nearly 18 million deaths annually and imposing substantial economic, social, and healthcare burdens (World Health Organization, 2021; Roth et al., 2020). The global epidemiology demonstrates significant regional disparities, with low- and middle-income countries experiencing disproportionately high CVD prevalence and premature mortality, whereas high-income countries have benefited from decades of risk factor control and advanced medical therapies (Prabhakaran et al., 2016; Ford & Capewell, 2011). The economic consequences of CVD are profound, including direct healthcare costs, productivity losses, and intangible impacts on quality of life, underscoring the urgency for comprehensive prevention strategies (Bloom et al., 2011).

CVD risk is driven by a combination of traditional factors, including hypertension, diabetes mellitus, dyslipidemia, and tobacco use, as well as lifestyle-related determinants such as physical inactivity, unhealthy diet, and obesity (Mills et al., 2020; Afshin et al., 2019; World Health Organization, 2020). Addressing these multifactorial risks requires integrative approaches that combine population-based interventions, high-risk individual strategies, and secondary prevention for patients with established disease. Evidence-based strategies, including tobacco control, salt and trans fat reduction, polypill therapy, and cardiac rehabilitation, have demonstrated efficacy in reducing CVD events and mortality, yet their implementation remains uneven, particularly in resource-limited settings (WHO Framework Convention on Tobacco Control, 2019; Anderson et al., 2016; Joseph et al., 2021).

Public health interventions, encompassing health system strengthening, community-based programs, workplace health initiatives, and digital health technologies, offer scalable opportunities to extend preventive care to broader populations. Integrating CVD prevention into primary healthcare, task-shifting to non-physician providers, and leveraging community health workers have shown measurable improvements in risk factor control and adherence, even in low-resource environments (Ogedegbe et al., 2014; Jeet et al., 2017; Chow et al., 2015). Digital tools, including mobile health platforms, wearable devices, and telemedicine, enable continuous monitoring, personalized feedback, and improved access to care, enhancing both effectiveness and equity of interventions (Steinhubl et al., 2015; Kitsiou et al., 2017).

Policy interventions and regulatory measures are critical levers for sustainable CVD prevention. Fiscal strategies, such as taxation of tobacco, alcohol, and sugar-sweetened beverages, alongside subsidies for healthy foods, have demonstrated substantial reductions in risk behaviors and improved population health outcomes (World Health Organization, 2015; Colchero et al., 2016; Afshin et al., 2017). Regulatory policies including food labeling, marketing restrictions, and urban design promoting physical activity further reinforce healthy choices and enable structural changes that support long-term cardiovascular health (Taillie et al., 2020; Sallis et al., 2016).

Cost-effectiveness analyses consistently demonstrate that both population-level and individual-based interventions provide substantial health and economic benefits, with population-wide policies such as salt reduction, trans fat elimination, and tobacco taxation offering high returns on investment (World Health Organization, 2018). Individual-focused strategies, including pharmacological therapies, diabetes management, and cardiac rehabilitation, remain cost-effective in high-risk populations, supporting their prioritization alongside broad population measures.

Despite these advances, significant implementation challenges persist. Resource limitations, workforce shortages, political barriers, industry opposition, low health literacy, and socioeconomic disparities constrain the effectiveness of prevention programs, particularly in LMICs (Verguet et al., 2015; Chow et al., 2015). Addressing these challenges requires multi-level, equity-focused strategies that combine health system strengthening, policy enforcement, community engagement, digital health integration, and continuous monitoring and evaluation to ensure sustainable and scalable impact.

Future directions in CVD prevention highlight the transformative potential of precision medicine, genomics, artificial intelligence, and digital health technologies. These innovations allow individualized risk prediction, targeted interventions, and real-time monitoring of cardiovascular health, offering opportunities to enhance both efficacy and efficiency (Khera et al., 2018; Ridker et al., 2019; Steinhubl et al., 2015). Additionally, the COVID-19 pandemic underscores the necessity of integrating non-communicable disease preparedness into global health security frameworks, ensuring that systems are resilient to both infectious and chronic disease threats (Clerkin et al., 2020; WHO, 2021).

In conclusion, the global burden of CVD necessitates comprehensive, multi-faceted prevention strategies that integrate population-level policies, high-risk individual approaches, health system strengthening, community engagement, and technological innovation. Evidence-based interventions are available and cost-effective, yet their full impact requires overcoming implementation barriers, ensuring equitable access, and adapting strategies to diverse sociocultural and economic contexts. By combining traditional public health measures with emerging precision and digital health innovations, the global community can achieve substantial reductions in CVD morbidity and mortality, improve quality of life, and enhance economic productivity, moving toward a future of sustainable and equitable cardiovascular health.

References

Afshin, A., Peñalvo, J. L., Del Gobbo, L., Silva, J., Michaelson, M., O'Flaherty, M., ... & Mozaffarian, D. (2017). The prospective impact of food pricing on improving dietary consumption: A systematic review and meta-analysis. PLoS One, 12(3), e0172277. https://doi.org/10.1371/journal.pone.0172277

Afshin, A., Sur, P. J., Fay, K. A., Cornaby, L., Ferrara, G., Salama, J. S., ... & Murray, C. J. (2019). Health effects of dietary risks in 195 countries, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 393(10184), 1958-1972. https://doi.org/10.1016/S0140-6736(19)30041-8

Anderson, L., Oldridge, N., Thompson, D. R., Zwisler, A. D., Rees, K., Martin, N., & Taylor, R. S. (2016). Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. Journal of the American College of Cardiology, 67(1), 1-12. https://doi.org/10.1016/j.jacc.2015.10.044

Bloom, D. E., Cafiero, E. T., Jané-Llopis, E., Abrahams-Gessel, S., Bloom, L. R., Fathima, S., ... & Weinstein, C. (2011). The global economic burden of noncommunicable diseases. Geneva: World Economic Forum.

Brown, M. T., & Bussell, J. K. (2011). Medication adherence: WHO cares? Mayo Clinic Proceedings, 86(4), 304-314. https://doi.org/10.4065/mcp.2010.0575

Chow, C. K., Redfern, J., Hillis, G. S., Thakkar, J., Santo, K., Hackett, M. L., ... & Rodgers, A. (2015). Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: A randomized clinical trial. JAMA, 314(12), 1255-1263. https://doi.org/10.1001/jama.2015.10945

Colchero, M. A., Popkin, B. M., Rivera, J. A., & Ng, S. W. (2016). Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: Observational study. BMJ, 352, h6704. https://doi.org/10.1136/bmj.h6704

Ford, E. S., & Capewell, S. (2011). Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: Public health versus clinical care. Annual Review of Public Health, 32, 5-22. https://doi.org/10.1146/annurev-publhealth-031210-101211

GBD 2017 Risk Factor Collaborators. (2018). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 392(10159), 1923-1994. https://doi.org/10.1016/S0140-6736(18)32225-6

Goetzel, R. Z., Henke, R. M., Tabrizi, M., Pelletier, K. R., Loeppke, R., Ballard, D. W., ... & White, J. (2014). Do workplace health promotion (wellness) programs work? Journal of Occupational and Environmental Medicine, 56(9), 927-934. https://doi.org/10.1097/JOM.0000000000000276

Guthold, R., Stevens, G. A., Riley, L. M., & Bull, F. C. (2018). Worldwide trends in insufficient physical activity from 2001 to 2016: A pooled analysis of 358 population-based surveys with 1·9 million participants. The Lancet Global Health, 6(10), e1077-e1086. https://doi.org/10.1016/S2214-109X(18)30357-7

Institute for Health Metrics and Evaluation. (2022). Global Health Data Exchange: GBD Results Tool. University of Washington. http://ghdx.healthdata.org/gbd-results-tool

Jeet, G., Thakur, J. S., Prinja, S., & Singh, M. (2017). Community health workers for non-communicable diseases prevention and control in developing countries: Evidence and implications. PLoS One, 12(7), e0180640. https://doi.org/10.1371/journal.pone.0180640

Joseph, P., Roshandel, G., Gao, P., Pais, P., Lonn, E., Xavier, D., ... & Yusuf, S. (2021). Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis. The Lancet, 398(10306), 1133-1146. https://doi.org/10.1016/S0140-6736(21)01827-4

Karppanen, H., & Mervaala, E. (2006). Sodium intake and hypertension. Progress in Cardiovascular Diseases, 49(2), 59-75. https://doi.org/10.1016/j.pcad.2006.07.001

Keates, A. K., Mocumbi, A. O., Ntsekhe, M., Sliwa, K., & Stewart, S. (2017). Cardiovascular disease in Africa: Epidemiological profile and challenges. Nature Reviews Cardiology, 14(5), 273-293. https://doi.org/10.1038/nrcardio.2017.19

Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16(4), 223-237. https://doi.org/10.1038/s41581-019-0244-2

Ogedegbe, G., Gyamfi, J., Plange-Rhule, J., Surkis, A., Rosenthal, D. M., Airhihenbuwa, C., ... & Cooper, R. (2014). Task shifting interventions for cardiovascular risk reduction in low-income and middle-income countries: A systematic review of randomised controlled trials. BMJ Open, 4(10), e005983. https://doi.org/10.1136/bmjopen-2014-005983

Prabhakaran, D., Jeemon, P., & Roy, A. (2016). Cardiovascular diseases in India: Current epidemiology and future directions. Circulation, 133(16), 1605-1620. https://doi.org/10.1161/CIRCULATIONAHA.114.008729

Reitsma, M. B., Fullman, N., Ng, M., Salama, J. S., Abajobir, A., Abate, K. H., ... & Gakidou, E. (2017). Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: A systematic analysis from the Global Burden of Disease Study 2015. The Lancet, 389(10082), 1885-1906. https://doi.org/10.1016/S0140-6736(17)30819-X

Restrepo, B. J., & Rieger, M. (2016). Denmark's policy on artificial trans fat and cardiovascular disease. American Journal of Preventive Medicine, 50(1), 69-76. https://doi.org/10.1016/j.amepre.2015.06.018

Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., ... & Fuster, V. (2020). Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. Journal of the American College of Cardiology, 76(25), 2982-3021. https://doi.org/10.1016/j.jacc.2020.11.010

Sallis, J. F., Bull, F., Guthold, R., Heath, G. W., Inoue, S., Kelly, P., ... & Hallal, P. C. (2016). Progress in physical activity over the Olympic quadrennium. The Lancet, 388(10051), 1325-1336. https://doi.org/10.1016/S0140-6736(16)30581-5